A decline in DNA repair mechanisms, coupled with an increase in mutation as cells age, means getting older is a major risk factor in the development of debilitating diseases among our global population.
Premature ageing (progeria) syndromes and age-related diseases including osteoporosis, cancer and neurodegenerative conditions including Alzheimer’s disease are all known to be associated with defects in DNA damage repair.
Our rigorous and robust research into understanding DNA damage repair has led to the development of multiple pathways towards solving age-related health issues. Diversification of our technologies not only enhances commercial viability for investors but also, and most importantly, provides a range of solutions for people to live a healthier life, for longer.
Our drug target research has resulted in the identification of a compound that restores DNA repair efficiency to prevent DNA damage-induced senescence. The CVP001 programme is targeting development of treatments for patients with osteoporosis and cancer. Its effects on neurodegenerative conditions including Alzheimer’s disease are also being explored in preclinical research.
Research into a predictive biomarker to determine response to cancer treatment with PARP inhibitors has resulted in the development of a new diagnostic test — CVP002 — with the potential to improve treatment selection and increase the number of patients who have the opportunity to benefit from PARP inhibitor therapy.